regulatory
confidence high
sentiment negative
materiality 0.75
ATHERSYS, INC / NEW: Nasdaq/NYSE listing notice — Athersys receives Nasdaq bid-price deficiency notice; 180 days to cure
ATHERSYS, INC / NEW
- Nasdaq notified Athersys on Dec 22, 2022 that bid price was below $1.00 for 30 consecutive business days.
- Company has until June 20, 2023 to regain compliance by closing at or above $1.00 for 10 consecutive days.
- Common stock continues trading on Nasdaq Capital Market during the cure period.
- Options include a potential reverse stock split; risk of delisting if not cured or extended.
- Failure to regain compliance may lead to delisting, with a possible appeal to Nasdaq Hearings Panel.